Novo Nordisk A/S ADR
(NVO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 7,933,230 | 7,690,185 | 6,652,436 | 6,165,080 | 5,900,895 |
| Cost of Goods | 1,147,762 | 1,179,026 | 1,143,126 | 974,160 | 867,867 |
| Gross Profit | 6,785,468 | 6,511,159 | 5,509,311 | 5,190,920 | 5,033,028 |
| Operating Expenses | 3,296,193 | 2,907,676 | 3,164,658 | 2,460,185 | 2,403,982 |
| Operating Income | 3,490,037 | 3,603,509 | 2,344,778 | 2,730,895 | 2,629,913 |
| Interest Expense | -94,527 | 161,680 | -338,261 | 503,993 | 465,036 |
| Other Income | -41,054 | 122,773 | -447,459 | 212,827 | 236,808 |
| Pre-tax Income | 3,543,510 | 3,564,602 | 2,235,580 | 2,439,729 | 2,401,685 |
| Income Tax | 705,079 | 709,404 | 369,578 | 490,733 | 497,211 |
| Net Income Continuous | 2,838,431 | 2,855,198 | 1,866,001 | 1,948,996 | 1,904,474 |
| Net Income | $2,838,431 | $2,855,198 | $1,866,001 | $1,948,996 | $1,904,474 |
| EPS Basic Total Ops | 0.63 | 0.64 | 0.41 | 0.43 | 0.42 |
| EPS Basic Continuous Ops | 0.63 | 0.63 | 0.41 | 0.43 | 0.42 |
| EPS Diluted Total Ops | 0.63 | 0.63 | 0.41 | 0.43 | 0.42 |
| EPS Diluted Continuous Ops | 0.63 | 0.63 | 0.51 | 0.43 | 0.42 |
| EBITDA(a) | $3,811,534 | $3,851,217 | $2,666,494 | $2,981,740 | $2,850,991 |